These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


237 related items for PubMed ID: 17229495

  • 41. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y, Qiu J, Zhou Y, Farhangfar F, Hester J, Lin AY, Decker WK.
    Vaccine; 2008 Jan 30; 26(5):614-22. PubMed ID: 18166249
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood.
    Biagini RE, Sammons DL, Smith JP, MacKenzie BA, Striley CA, Snawder JE, Robertson SA, Quinn CP.
    Clin Vaccine Immunol; 2006 May 30; 13(5):541-6. PubMed ID: 16682473
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
    Gupta M, Alam S, Bhatnagar R.
    Vaccine; 2007 Dec 05; 25(50):8410-9. PubMed ID: 17980467
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.
    Brady RA, Verma A, Meade BD, Burns DL.
    Clin Vaccine Immunol; 2010 Sep 05; 17(9):1390-7. PubMed ID: 20631338
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
    Klinman DM, Xie H, Ivins BE.
    Ann N Y Acad Sci; 2006 Oct 05; 1082():137-50. PubMed ID: 17145935
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.
    Oscherwitz J, Quinn CP, Cease KB.
    Vaccine; 2015 May 11; 33(20):2342-6. PubMed ID: 25820066
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW.
    Vaccine; 2014 Nov 28; 32(50):6847-54. PubMed ID: 24530403
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials.
    Soroka SD, Schiffer JM, Semenova VA, Li H, Foster L, Quinn CP.
    Biologicals; 2010 Nov 28; 38(6):675-83. PubMed ID: 20875951
    [Abstract] [Full Text] [Related]

  • 58. Past, imminent and future human medical countermeasures for anthrax.
    Baillie LW.
    J Appl Microbiol; 2006 Sep 28; 101(3):594-606. PubMed ID: 16907809
    [Abstract] [Full Text] [Related]

  • 59. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M, Hine PM, James Jackson W, Giri L, Nabors GS.
    Vaccine; 2007 Jan 05; 25(3):526-34. PubMed ID: 16973247
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.